Published in Women's Health Weekly, March 23rd, 2006
Fispemifene is the company's product candidate for the treatment of the symptoms of andropause. This first randomized, double-blind, placebo-controlled, parallel group phase II study of fispemifene in the treatment of low testosterone in older men will seek to enroll approximately 100 patients at approximately 20 study sites in the United States. Patients will receive either 100, 200, or 300 mg fispemifene or placebo for 28 days.
The company also started dosing in a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly